{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:10:20Z","timestamp":1770070220758,"version":"3.49.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaad.2021.12.068","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T03:20:42Z","timestamp":1645500042000},"page":"21-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma"],"prefix":"10.1016","volume":"87","author":[{"given":"Vijay","family":"Kodumudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorin A.","family":"Bibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas A.","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Shahriari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Skudalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sueheidi","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib1","first-page":"494","article-title":"Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA","volume":"155","author":"Pinard","year":"2019","journal-title":"Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/09546634.2017.1403549","article-title":"Recent developments on treatment strategies and the prognosis of dermatomyositis: a review","volume":"29","author":"Isak","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"issue":"27","key":"10.1016\/j.jaad.2021.12.068_bib6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Anh-Tu Hoa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib8","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib11","first-page":"29","article-title":"High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels","volume":"10","author":"G\u00f6ttfried","year":"2000","journal-title":"Eur J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.068_bib12","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","article-title":"Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease","volume":"28","author":"Bounfour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.14726","article-title":"Treatment of clinically amyopathic dermatomyositis in adults: a systematic review","volume":"179","author":"Callander","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaad.2008.09.051","article-title":"Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin","volume":"60","author":"Pe\u00f1ate","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s10067-006-0337-8","article-title":"Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","article-title":"Treatment of dermatomyositis with intravenous gammaglobulin","volume":"91","author":"Lang","year":"1991","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2340\/00015555-0016","article-title":"Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin","volume":"86","author":"Kuwano","year":"2006","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1346-8138.1999.tb02026.x","article-title":"Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions","volume":"26","author":"Sadayama","year":"1999","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: A retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u2018ProDERM Study\u2019)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry","volume":"38","author":"Bader-Meunier","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib26","first-page":"601","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis","volume":"52","author":"Levine","year":"2005","journal-title":"Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","article-title":"Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases","volume":"56","author":"Dinh","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib29","first-page":"314","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis","volume":"65","author":"Oddis","year":"2013","journal-title":"Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00296-019-04467-6","article-title":"Biologic therapy in the idiopathic inflammatory myopathies","volume":"40","author":"Khoo","year":"2020","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.12.068_bib38","first-page":"4073879","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Rep Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2021.12.068_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib\u2014a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"8S","key":"10.1016\/j.jaad.2021.12.068_bib49","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis","volume":"27","author":"Kato","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib50","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.068_bib51","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: a concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from two academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.068_bib55","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","article-title":"Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series","volume":"60","author":"Shneyderman","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib56","first-page":"371","article-title":"Long-term extension study of tofacitinib in refractory dermatomyositis. Arthritis","volume":"74","author":"Paik","year":"2022","journal-title":"Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib57","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate","volume":"59","author":"S\u00f6zeri","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib58","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1016\/j.jaad.2021.12.068_bib59","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with Ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib60","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib61","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/rheumatology\/keaa184","article-title":"Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis","volume":"59","author":"Delvino","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib63","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib64","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"le Voyer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib65","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib66","first-page":"191","article-title":"Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case","volume":"5","author":"Bitar","year":"2019","journal-title":"Rep"},{"issue":"8S","key":"10.1016\/j.jaad.2021.12.068_bib67","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1097\/RHU.0000000000000999","article-title":"Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast","volume":"27","author":"Charlton","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jdcr.2019.08.006","article-title":"Apremilast as an adjuvant therapy for calcinosis cutis","volume":"5","author":"Qiblawi","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib69","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib70","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1093\/rheumatology\/keaa698","article-title":"Infliximab in a patient with treatment-resistant anti-SAE dermatomyositis","volume":"60","author":"Hassan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12859","article-title":"Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis","volume":"32","author":"Yamada-Kanazawa","year":"2019","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib72","first-page":"79","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Res Ther"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib73","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","article-title":"Treatment of early and refractory dermatomyositis with infliximab: a report of two cases","volume":"26","author":"Dold","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib74","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","article-title":"Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review","volume":"33","author":"Chen","year":"2013","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up","volume":"52","author":"Hengstman","year":"2004","journal-title":"Eur Neurol"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib76","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/RHU.0000000000000514","article-title":"Successful treatment of refractory juvenile dermatomyositis with adalimumab","volume":"23","author":"Wang","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib78","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/ced.14325","article-title":"Successful treatment of dermatomyositis and associated calcinosis with adalimumab","volume":"45","author":"Xie","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib80","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ana.22624","article-title":"Etanercept as steroid-sparing agent in dermatomyositis","volume":"70","author":"Brunasso","year":"2011","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib81","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3899\/jrheum.091413","article-title":"Dermatomyositis during adalimumab therapy for rheumatoid arthritis","volume":"37","author":"Brunasso","year":"2010","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib82","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib83","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jaad.2013.11.012","article-title":"Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis","volume":"70","author":"Dicaro","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib84","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","article-title":"A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept","volume":"30","author":"Ishikawa","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib85","first-page":"1307","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care","volume":"65","author":"Hall","year":"2013","journal-title":"Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib86","first-page":"192","article-title":"Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis","volume":"39","author":"Riolo","year":"2012","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.alit.2017.09.001","article-title":"A case of clinically\u00a0amyopathic dermatomyositis that developed during Anti-TNF-\u03b1 therapy for rheumatoid arthritis","volume":"67","author":"Takata","year":"2018","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib88","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: A mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib89","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","article-title":"A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14712","article-title":"NXP2-positive dermatomyositis complicated with refractory skin edema: successful treatment with tocilizumab","volume":"34","author":"Lu","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0000000000000430","article-title":"A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab","volume":"23","author":"Montoya","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib94","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.12.068_bib36","unstructured":"A study to evaluate VIB7734 in participants with systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sjogren\u2019s syndrome, systemic sclerosis, polymyositis, and dermatomyositis. Clin Trials.gov identifier: NCT03817424. Accessed August 14, 2021."},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib99","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis","volume":"77","author":"Aggarwal","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.12.068_bib100","author":"Efficacy"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib109","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2020.07.122","article-title":"A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7\/8\/9 antagonist, IMO-8400, in dermatomyositis","volume":"84","author":"Kim","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.12.068_bib115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/berh.1999.0075","article-title":"Scleroderma and related disorders: therapeutic aspects","volume":"14","author":"Denton","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.068_bib117","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib118","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib119","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"25","key":"10.1016\/j.jaad.2021.12.068_bib120","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.068_bib122","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib123","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the TH1\/TH2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib127","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a Phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.068_bib129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib139","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/BRS.0b013e3181a1390d","article-title":"Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society","volume":"34","author":"Chou","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib130","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2021.12.068_bib131","author":"Khanna"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib133","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","article-title":"Clinical efficacy and safety of cilostazol: a critical review of the literature","volume":"75","author":"Rogers","year":"2015","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib134","first-page":"CD003748","article-title":"Cilostazol for intermittent claudication","volume":"2014","author":"Bedenis","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2021.12.068_bib135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10238-015-0370-5","article-title":"Efficacy of cilostazol for the treatment of Raynaud\u2019s phenomenon in systemic sclerosis patients","volume":"16","author":"Negrini","year":"2016","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jaad.2021.12.068_bib136","doi-asserted-by":"crossref","unstructured":"Rajagopalan S, Pfenninger D, Somers E, et\u00a0al. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol. 2033;92(11):1310-1315. https:\/\/doi.org\/10.1016\/j.amjcard.2003.08.013","DOI":"10.1016\/j.amjcard.2003.08.013"},{"key":"10.1016\/j.jaad.2021.12.068_bib137","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","article-title":"The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.068_bib138","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4suppl 113","key":"10.1016\/j.jaad.2021.12.068_bib141","first-page":"146","article-title":"Randomised, double-blind, placebo-controlled trial of IL1-trap, Rilonacept, in systemic sclerosis. A phase I\/II biomarker trial","volume":"36","author":"Mantero","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.068_bib142","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by Macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib143","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2229-5178.93484","article-title":"Endothelin-1 in systemic sclerosis","volume":"3","author":"Aghaei","year":"2012","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib144","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/187152811794352088","article-title":"Endothelin receptor antagonists as disease modifiers in systemic sclerosis","volume":"10","author":"Shetty","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.068_bib146","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib147","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/keq077","article-title":"Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial","volume":"49","author":"Kuhn","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.068_bib148","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00296-016-3582-4","article-title":"Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen","volume":"37","author":"Foti","year":"2017","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib149","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/ard.40.4.350","article-title":"Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis","volume":"40","author":"Martin","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib152","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-019-04863-0","article-title":"Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)","volume":"39","author":"Mecoli","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.068_bib153","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Garcia-Gonzalez","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib154","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ard.2010.137539","article-title":"The cannabinoid WIN55,212-2 abrogates dermal fibrosis in scleroderma bleomycin model","volume":"70","author":"Balistreri","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.068_bib155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.068_bib156","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Garcia-Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.068_bib157","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.068_bib172","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.068_bib173","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B injection for Raynaud\u2019s phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:02:18Z","timestamp":1759273338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222003279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0190962222003279"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.068","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(22)00831-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}